CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 289 enrolled
Drug / intervention
magnesium oxide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01439945
NCT01439945Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes

Alliance for Clinical Trials in Oncology·interventional·Posted Sep 23, 2011·Updated Apr 4, 2017

In Brief

A Phase 2 clinical trial evaluating magnesium oxide and placebo for Breast Cancer and 2 related conditions. Completed, enrolled 289 participants across 283 sites.

Detailed Summary

RATIONALE: Magnesium oxide may help relieve hot flashes symptoms in women with a history of breast cancer. PURPOSE: This randomized clinical trial studies how well a high-dose or a low-dose of magnesium oxide works compared to placebo in treating menopausal women with hot flashes and a history of breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Cancer Survivor, Hot Flashes
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 23, 2011
Enrollment StartSep 1, 2011
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.8 years ago

Interventions

magnesium oxidedrug

Given PO

placeboother

Given PO